Therefore, the International Panel for NMO Diagnosis (IPND) has recently introduced new nomenclature and new diagnostic criteria based on the presence of AQP4 antibodies in patients’ serum [25]. This evidence concerns the gene AQP4 and neuromyelitis optica.